The Pharm of Old McDonald 8

Home > Preview

The flashcards below were created by user countchocula58 on FreezingBlue Flashcards.


  1. glulisine
    • rapid acting, binds insulin receptor (tyrosine kinase) to increase stored glucose as glycogen in the liver, muscles, increasing protein synthesis and potassium uptake in muscles, and triglyceride storage in fat cells. Type 1 DM, type 2, postprandial control (rapid acting)
    • hypoglycemia, lipodystrophy, hypersensitivity(rare)
    • quickly glu your ass lis chaps after dinner (rapid, glulisine, aspart, lispro, postprandial)
  2. lispro
    • rapid acting, binds insulin receptor (tyrosine kinase) to increase stored glucose as glycogen in the liver, muscles, increasing protein synthesis and potassium uptake in muscles, and triglyceride storage in fat cells. Type 1 DM, type 2, postprandial control (rapid acting), gestational DM
    • hypoglycemia, lipodystrophy, hypersensitivity(rare)
    • quickly glu your ass lis chaps after dinner (rapid, glulisine, aspart, lispro, postprandial)
  3. aspart
    • rapid acting, binds insulin receptor (tyrosine kinase) to increase stored glucose as glycogen in the liver, muscles, increasing protein synthesis and potassium uptake in muscles, and triglyceride storage in fat cells. Type 1 DM, type 2, gestational DM
    • hypoglycemia, lipodystrophy, hypersensitivity(rare)
    • quickly glu your ass lis chaps after dinner (rapid, glulisine, aspart, lispro, postprandial)
  4. regular insulin
    • short acting(quick[but not "rapid"] onset with quick offset), binds insulin receptor (tyrosine kinase) to increase stored glucose as glycogen in the liver, muscles, increasing protein synthesis and potassium uptake in muscles, and triglyceride storage in fat cells. Type 1 DM, type 2, gestational DM, hyperkalemia treatment (given with glucose), stress hyperglycemia
    • the LAGging RN is a DoG
  5. neutral protamine hagedorn
    • aka NPH, intermediate acting insulin
    • intermediate acting binds insulin receptor (tyrosine kinase) to increase stored glucose as glycogen in the liver, muscles, increasing protein synthesis and potassium uptake in muscles, and triglyceride storage in fat cells. Type 1 DM, type 2, gestational DM
  6. detemir
    • long acting insulin, binds insulin receptor (tyrosine kinase) to increase stored glucose as glycogen in the liver, muscles, increasing protein synthesis and potassium uptake in muscles, and triglyceride storage in fat cells. Type 1 DM, type 2, gestational DM, basal glucose control
    • indeterminate amount of time (detemir, long acting)
  7. glargine
    • long acting insulin, binds insulin receptor (tyrosine kinase) to increase stored glucose as glycogen in the liver, muscles, increasing protein synthesis and potassium uptake in muscles, and triglyceride storage in fat cells. Type 1 DM, type 2, gestational DM, basal glucose control
    • largest amount of time (glargine, longest acting)
  8. metformin
    • biguanide
    • reduces gluconeogenesis, increases glycolysis, increases peripheral glucose uptake, inreases insulin sensitivity. 1st line in type 2, can even be used in type 1
    • weight loss, GI upset, lactic acidosis (contraindicated in renal insufficiency)
  9. sulfonylureas
    • 1st gen chlorpropamide, tolbutamide
    • 2nd gen glimepiride, glipizide, glyburide
    • close K+ channel in beta islet cells to depolarize and increase insulin release by increased Ca influx. Type 2 DM
    • hypoglycemia(esp with renal failure), weight gain
  10. chlorpropamide (class/special?)
    • 1st gen sulfonylureas (close K+ channel in beta islet cells to depolarize and increase insulin release by increased Ca influx). Type 2 DM
    • disulfram like
  11. tolbutamide (class/special?)
    • 1st gen sulfonylureas (close K+ channel in beta islet cells to depolarize and increase insulin release by increased Ca influx). Type 2 DM
    • disulfram like
  12. glimepiride (class/special?)
    • 2nd gen sulfonylureas (close K+ channel in beta islet cells to depolarize and increase insulin release by increased Ca influx). Type 2 DM
    • hypoglycemia
  13. glipizide (class/special?)
    • 2nd gen sulfonylureas (close K+ channel in beta islet cells to depolarize and increase insulin release by increased Ca influx). Type 2 DM
    • hypoglycemia
  14. glyburide (class/special?)
    • 2nd gen sulfonylureas (close K+ channel in beta islet cells to depolarize and increase insulin release by increased Ca influx). Type 2 DM
    • hypoglycemia
  15. pioglitazone
    • binds PPAR-gamma nuclear transcription receptor increasing genes for adiponecting(increased fatty acid storage), insulin sensitivity(increased glucose metabolism). Type 2 DM
    • safe in renal impairment, HF, hepatotox, fracture risk, weight gain
    • glitterzone the sugar steroid makes your peepee AlRight(-glitazone, insulin sensitivity, fatty acid storage, steroid binding, renal spared but everything else dies, PPARgamma)
  16. rosiglitazone
    • binds PPAR-gamma nuclear transcription receptor increasing genes for adiponecting(increased fatty acid storage), insulin sensitivity(increased glucose metabolism). Type 2 DM
    • safe in renal impairment, HF, hepatotox, fracture risk, weight gain
    • glitterzone the sugar steroid makes your peepee AlRight(-glitazone, insulin sensitivity, fatty acid storage, steroid binding, renal spared but everything else dies, PPARgamma)
  17. nateglinide
    • meglitinide
    • binds to different site on K channel(than sulfonylureas), closing K+ channel in beta islet cells to depolarize and increase insulin release by increased Ca influx. Type 2 DM
    • hypoglycemia, weight gain
  18. repaglinide
    • binds to different site on K channel(than sulfonylureas), closing K+ channel in beta islet cells to depolarize and increase insulin release by increased Ca influx. Type 2 DM
    • hypoglycemia, weight gain
  19. exenatide
    • glucagon like peptide-1 (GLP-1), negative feedback on glucagon to decrease glucagon release, glucagon effect of increased glucose-dependent insulin release, decreasing glucagon release, slows gastric emptying, increasing satiety. Type 2 DM
    • modest weight loss, nausea, vomiting, pancreatitis, degraded by dipeptidyl peptidase (DPP-4)
    • liter of exenogenous glucagon tide (liraglutide, exenatide, glucagon like peptide 1)
  20. liraglutide
    • glucagon like peptide-1 (GLP-1), negative feedback on glucagon to decrease glucagon release, glucagon effect of increased glucose-dependent insulin release, decreasing glucagon release, slows gastric emptying, increasing satiety, subQ injection. Type 2 DM
    • modest weight loss, nausea, vomiting, pancreatitis, degraded by dipeptidyl peptidase (DPP-4)
    • liter of exenogenous glucagon tide (liraglutide, exenatide, glucagon like peptide 1)
  21. linagliptin
    • inhibitor of dipeptidyl peptidase (DPP-4), increasing the effect of exenatide (glucagon like peptide-1). Type 2 DM
    • urinary/respiratory infections
    • lean on, sit on, have sex on DPP-4 (linagliptin, sitagliptin, saxagliptin, inhibit DPP-4)
  22. sitagliptin
    • inhibitor of dipeptidyl peptidase (DPP-4), increasing the effect of exenatide (glucagon like peptide-1). Type 2 DM
    • urinary/respiratory infections
    • lean on, sit on, have sex on DPP-4 (linagliptin, sitagliptin, saxagliptin, inhibit DPP-4)
  23. saxagliptin
    • inhibitor of dipeptidyl peptidase (DPP-4), increasing the effect of exenatide (glucagon like peptide-1). Type 2 DM
    • urinary/respiratory infections
    • lean on, sit on, have sex on DPP-4 (linagliptin, sitagliptin, saxagliptin, inhibit DPP-4)
  24. pramlintide
    • amylin analog to delay gastric emptying and decrease glucagon, subQ injection. Type 2 and apparently type 1 DM
    • hypoglycemia, nausea
  25. canagliflozin
    • sodium-glucose-cotransporter 2 (SGLT2) inhibition to block PCT glucose reabsorption. Type 2 DM
    • glycosuria (UTIs, vaginal yeast infections), hyperkalemia, dehydration (orthostatic hypotension)
    • flowin' with -flozins (glucosuria, -flozins)
  26. dapagliflozin
    • sodium-glucose-cotransporter 2 (SGLT2) inhibition to block PCT glucose reabsorption. Type 2 DM
    • glycosuria (UTIs, vaginal yeast infections), hyperkalemia, dehydration (orthostatic hypotension)
    • flowin' with -flozins (glucosuria, -flozins)
  27. empagliflozin
    • sodium-glucose-cotransporter 2 (SGLT2) inhibition to block PCT glucose reabsorption. Type 2 DM
    • glycosuria (UTIs, vaginal yeast infections), hyperkalemia, dehydration (orthostatic hypotension)
    • flowin' with -flozins (glucosuria, -flozins)
  28. acarbose
    • inhibition of brush border alpha-glucosidase, delaying carbohydrate hydrolysis, to reduce glucose absorption. Type 2 DM
    • GI disturbance
    • a carbohydrate MIGht give you gas (a carbose, miglitol, GI disturbance)
  29. miglitol
    • inhibition of brush border alpha-glucosidase, delaying carbohydrate hydrolysis, to reduce glucose absorption. Type 2 DM
    • GI disturbance
    • a carbohydrate MIGht give you gas (a carbose, miglitol, GI disturbance)
  30. propylthiouracil
    • aka PTU
    • thionamide
    • block thyroid peroxidase to inhibit oxidation of iodide, organification, and transport, also blocks 5'-deiodinase to reduce peripheral conversion of T4->T3. Hyperthyroidism
    • not a teratogen, skin rash, agranulocytosis, aplastic anemia, hepatotox
    • Ptu (blocks peripheral conversion, safe in pregnancy[compared to methimazole])
  31. methimazole
    • thionamide
    • block thyroid peroxidase to inhibit oxidation of iodide, organification, and transport. Hyperthyroidism
    • aplasia cutis(teratogen), skin rash, agranulocytosis, aplastic anemia, hepatotox
    • Ptu (blocks peripheral conversion, safe in pregnancy[compared to methimazole])
  32. levothyroxine
    • T4, converted to T3 as needed. Hypothyroidism, myxedema, weight loss (off label)
    • tachycardia, heat intolerance, tremor, arrhythmia
  33. triiodothyronine
    • T3 replacement. Hypothyroidism, myxedema, weight loss (off label)
    • tachycardia, heat intolerance, tremor, arrhythmia
  34. conivaptan
    • block ADH at the V2 receptor. SIADH
    • VAsoPressin Two ANti (anti V2, -vaptan)
  35. tolvaptan
    • block ADH at the V2 receptor. SIADH
    • VAsoPressin Two ANti (anti V2, -vaptan)
  36. desmopressin acetate
    agonist on V2 receptors. Central DI
  37. growth hormone
    replaces growth hormone. Turner syndrome
  38. pitocin
    oxytocin, stimulating uterine contractions and milk letdown. Uterine hemorrhage, induction of labor
  39. octreotide
    somatostatin analog, inhibits just about everything. Acromegally, carcinoid syndrome, gastrinoma, glucagonoma, esophageal varices
  40. demeclocycline
    • ADH antagonist to block V2 receptors. SIADH
    • nephrogenic DI, photosensitivity, abnormalities of bones and teeth
    • tetracycline family (teethracyclines)
  41. glucocorticoids
    • beclomethasone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, triamcinolone
    • bind to IkappaB to inhibit NFkappaB(reduce COX-2 and others) and other transcription factors also directly inhibit phosophlipase A2 (decreasing arachidoinic acid formation)metabolic, catabolic, anti-inflammatory, immunosupression. Adrenal insufficiency, inflammation, immunosupression, asthma
    • Cushing syndrome (HTN, weight gain, moon facies, truncal obesity, buffalo hump, skin thinning, striae, acne, osteoporosis, hyperglycemia, amenorrhea, immunosupression), adrenocortical atrophy(adrenal insufficiency if no taper), peptic ulcers, steroid diabetes, steroid psychosis, cataracts
  42. beclomethasone (class/special?)
    glucocorticoid
  43. dexamethasone (class/special?)
    glucocorticoid
  44. hydrocortisone (class/special?)
    glucocorticoid
  45. methylprednisolone (class/special?)
    glucocorticoid
  46. predisone (class/special?)
    glucocorticoid. CLL, non-Hodgkin lymphoma
  47. prednisolone (class/special?)
    glucocorticoid. CLL, non-Hodgkin lymphoma
  48. triamcinolone (class/special?)
    glucocorticoid
  49. fludrocortisone
    • mostly aldosterone action with very little glucocorticoid effecst. Mineralocorticoid replacement in primary adrenal insufficiency
    • some glucocorticoid effects, edema, heart failure exacerbation, hyperpigmentation
    • flowdropcortisone (decrease urinary flow[aldosterone], fludrocortisone)
  50. cinacalcet
    • sensitization of CaSR to Ca levels to reduce PTH. Primary or secondary hyperparathyroidism
    • hypocalcemia
    • sensiCaset (sensitizes Ca set point, cinacalcet)
  51. leuprolide
    • GnRH super agonist. Infertility when pulsatile, continuous for uterine fibroids, endometriosis, precocious puberty, prostate cancer
    • superLou!
  52. ethinyl estradiol
    • binds all estrogen receptors. Hypogonadism, ovarian failure, menstrual abnormalities, hormone replacement therapy, prostate cancer, combined with progesterone
    • endometrial cancer, bleeding in postmenopausal women, thrombi, contraindicated if history of ER breast cancer or DVTs
  53. DES
    • binds all estrogen receptors. Hypogonadism, ovarian failure, menstrual abnormalities, hormone replacement therapy, prostate cancer, combined with progesterone
    • clear cell adenocarcinoma with gestational exposure, endometrial cancer, bleeding in postmenopausal women, thrombi, contraindicated if history of ER breast cancer or DVTs
  54. mestranol
    • binds all estrogen receptors. Hypogonadism, ovarian failure, menstrual abnormalities, hormone replacement therapy, prostate cancer, combined with progesterone
    • endometrial cancer, bleeding in postmenopausal women, thrombi, contraindicated if history of ER breast cancer or DVTs
  55. clomiphene
    • estrogen receptor antagonist at the hypthalamus, reducing negative feedback, increasing LH and FSH, stimulating ovulation. Infertility in PCOS and others
    • hot flashes, ovarian enlargement, twins/triplets etc, visual disturbances
  56. tamoxifen
    • antagonist on the breast, agonist at all other receptors. ER/PR breast cancer treatment and prevention
    • DVTs, endometrial cancer, no risk of osteoporosis
  57. raloxifene
    • antagonist on the breast and uterus, agonist elsewhere. Breast cancer prevention (NOT treatment)
    • DVTs, no risk of osteoporosis or endometrial cancer
  58. anastrozole
    inhibition of aromatase to reduce peripheral estrogen conversion. ER breast cancer in postmenopausal women
  59. letrozole
    inhibition of aromatase to reduce peripheral estrogen conversion. ER breast cancer in postmenopausal women
  60. exemstane
    inhibition of aromatase to reduce peripheral estrogen conversion. ER breast cancer in postmenopausal women

Card Set Information

Author:
countchocula58
ID:
318293
Filename:
The Pharm of Old McDonald 8
Updated:
2016-04-05 16:33:22
Tags:
tubblery tubblish step one pharm pharmacology
Folders:

Description:
Become a pharmacist!
Show Answers:

Home > Flashcards > Print Preview